Real World Evidence of Bempedoic Acid on Efficacy and Safety in Patients with Uncontrolled LDL-c and at High Risk of CVD

Simple item page
dc.contributor.authorManoj, Sen_US
dc.contributor.authorShah, Jen_US
dc.contributor.authorKumar, Den_US
dc.contributor.authorPradhan, Aen_US
dc.contributor.authorKinare, A. Ben_US
dc.contributor.authorSharma, A. Ken_US
dc.contributor.authorAditya, M. Sen_US
dc.contributor.authorRaj, R. Aen_US
dc.contributor.authorRaina, A. Aen_US
dc.contributor.authorPatel, Aen_US
dc.contributor.authorDas, Ben_US
dc.contributor.authorBathe, D. Sen_US
dc.contributor.authorMuchhala, Sen_US
dc.contributor.authorJhaveri, K.en_US
dc.date.accessioned2023-07-21T11:29:43Z
dc.date.available2023-07-21T11:29:43Z
dc.date.issued2023-06
dc.description.abstractBackground and Objective: Cardiovascular disease (CVD) is a significant cause of morbidity and mortality worldwide, with high-risk patients requiring effective management to reduce their risk of cardiovascular events. Bempedoic acid is a novel therapeutic agent recently approved as an add-on therapy to statins in patients with uncontrolled LDL-c. Bempedoic acid inhibits cholesterol synthesis in the liver, which ultimately reduces the risk of cardiovascular events. Therefore, the present study aims to assess the efficacy and safety of bempedoic acid in patients with uncontrolled LDL-c (Previously on moderate or high-intensity statins) with a high risk of CVD in real-world settings. Methods: This is a multicenter, retrospective, observational study on the data of high-risk-CVD patients collected from Bempedoic Acid on Efficacy and Safety in patients (BEST) Registry. The clinical data of 140 patients who were already on statin therapy and were receiving Bempedoic acid at a dose of 180 mg, along with measurements of the level of LDL-c, HbA1c, HDL, TG, TC, PPPG, FPG, AST, ALT, serum creatinine was taken into consideration. The primary outcome includes a change in LDL-c level, and secondary outcomes involve a change in the level of HbA1c, HDL, TG, TC, PPPG, FPG, AST, ALT, and serum creatinine at week 12 and 24. Adverse events were reported at both time points. Results: A total of 140 patients were included in the present study with a mean age of 51.8 ± 9.2 years and had primary confirmed diagnosis of dyslipidemia with uncontrolled LDL-c. The mean levels of LDL-c decreased from the mean baseline value of 142.67 ± 46.49 mg/dL, to 106.78 ±33.92 mg/d; a statistically significant reduction by 23.23% (p < 0.01) at week 12. Similarly, at week 24, the mean LDL-c value reduced to 90.39 ± 38.89 mg/dL. A 33.38 % decrease was observed (p < 0.01). Other parameters such as non-HDL, FPG, PPPG, AST and serum creatinine also showed statistically significant reduction at week 12 and week 24. Conclusion: The present study demonstrates that bempedoic acid is an effective add-on medication in lowering LDL-c levels in high-risk CVD patients with uncontrolled LDL-c.en_US
dc.identifier.affiliationsKauvery Hospital, Chennai, TamilNadu, Indiaen_US
dc.identifier.affiliationsHCG Hospital, Ahmedabad, Gujarat, Indiaen_US
dc.identifier.affiliationsMedica Superspecialty Hospital, Kolkata, West Bengal, Indiaen_US
dc.identifier.affiliationsKing George's Medical University, Lucknow, Uttar Pradesh, Indiaen_US
dc.identifier.affiliationsSamadhan Heart Centre, Jabalpur, Madhya Pradesh, Indiaen_US
dc.identifier.affiliationsFortis Escort Hospital, Jaipur, Rajasthan, Indiaen_US
dc.identifier.affiliationsYashoda Hospital, Secunderabad, Telangana, Indiaen_US
dc.identifier.affiliationsBhagwan Mahavir Jain Hospital, Bangalore, Karnataka, Indiaen_US
dc.identifier.affiliationsSubDistrict Hospital, Seer Hamdan, Anantnag, Jammu & Kashmir, Indiaen_US
dc.identifier.affiliationsJaynil Hospital, Vadodara, Gujarat, Indiaen_US
dc.identifier.affiliationsMurshidabad Medical College, Behrampore, West Bengal, Indiaen_US
dc.identifier.affiliationsLifeline Medical, Durgapur, West Bengal, India.en_US
dc.identifier.affiliationsZydus Lifesciences Limited, Mumbai, Maharashtra, India.en_US
dc.identifier.citationManoj S, Shah J, Kumar D, Pradhan A, Kinare A. B, Sharma A. K, Aditya M. S, Raj R. A, Raina A. A, Patel A, Das B, Bathe D. S, Muchhala S, Jhaveri K. Real World Evidence of Bempedoic Acid on Efficacy and Safety in Patients with Uncontrolled LDL-c and at High Risk of CVD. Cardiology and Angiology: An International Journal. 2023 Jun; 12(4): 113-122en_US
dc.identifier.issn2347-520X
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/220330
dc.languageenen_US
dc.publisherSciencedomain Internationalen_US
dc.relation.issuenumber4en_US
dc.relation.volume12en_US
dc.source.urihttps://doi.org/10.9734/ca/2023/v12i4350en_US
dc.subjectACL inhibitoren_US
dc.subjectBempedoic Acid (BA)en_US
dc.subjectCardiovascular Diseases (CVDs)en_US
dc.subjectdyslipidemiaen_US
dc.subjectLow-Density Lipoprotein Cholesterol (LDL-c).en_US
dc.titleReal World Evidence of Bempedoic Acid on Efficacy and Safety in Patients with Uncontrolled LDL-c and at High Risk of CVDen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
CA2023v12n4p113.pdf
Size:
621.57 KB
Format:
Adobe Portable Document Format
Download
Collections
Cardiology and Angiology: An International Journal